Global Crohn’s Disease Treatment Market, by Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 10.92 Billion in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increased approvals by regulatory bodies to key players for the drugs used to treat crohn’s disease is expected to drive market growth over the forecast period. For instance, in March 2020, Takeda Pharmaceutical Company Limited had announced that the gut-selective biologic Entyvio (vedolizumab) was approved by China’s National Medical Products Administration (NMPA) for the treatment of patients with moderate to severe active ulcerative colitis (UC) and crohn's disease (CD).
Global Crohn’s Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.
The COVID-19 pandemic had a significant impact on the crohn’s disease treatment market. For instance, according to an article published by the British medical journal (BMJ) in 2020, a nationwide study of paediatric gastroenterology IBD centers in the U.K., detailing the impact of the COVID-19 pandemic on the diagnosis and management of patients with IBD during the month of April 2020 was carried out. As per the study outcomes, COVID-19 had significantly impacted the pediatric endoscopy for inflammatory bowel disease (IBD) in the UK. Only two sites (10%) reported access to routine endoscopy for patients with IBD during April. Moreover, over 50% of children and young people presenting with a suspected diagnosis of IBD were diagnosed without a histological diagnosis due to restrictions placed on endoscopy at over 90% of centers across the U.K.
Global Crohn’s Disease Treatment Market: Key Developments
On June 17, 2022, Sandoz, a global leader in generic and biosimilar medicines, announced that the European Medicines Agency (EMA) had accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab) for regulatory review. The application includes all indications covered by the reference medicine, including rheumatoid arthritis, crohn's disease, ulcerative colitis, plaque psoriasis, and uveitis.
In February 2021, Celltrion Healthcare announced that the European Commission (EC) had granted marketing authorization for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases including Crohn’s disease (CD) and pediatric Crohn’s disease (pCD).
Browse 34 Market Data Tables and 38 Figures spread through 150 Pages and in-depth TOC on “Global Crohn’s Disease Treatment Market”- Forecast to 2030, Global Crohn’s Disease Treatment Market, by Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in Global Crohn’s Disease Treatment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/crohns-disease-treatment-market-1237
Moreover, increasing research and development activities by researchers to develop clinical lab test to predict disease course in pediatric patients with Crohn's disease is expected to drive market growth over the forecast period. For instance, in January 2021, Crohn's & Colitis Foundation, the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), had entered into a partnership with LifeArc, an independent medical research charity that advances translation of early science into health care treatments or diagnostics, to potentially develop the first clinical lab test to predict disease course in pediatric patients with Crohn's disease and response to treatment. A prognostic test which could accurately predict which children will develop complications and identify patients most likely to benefit from anti-TNF therapy would help clinicians make effective early treatment decisions to improve outcomes.
Key Takeaways of the Global Crohn’s Disease Treatment Market:
- Global crohn’s disease treatment market is expected to exhibit a CAGR of 4.2% during the forecast period due to increasing prevalence of inflammatory bowel diseases. For instance, according to the UCLA Center for Inflammatory Bowel Disease (IBD), approximately 1.6 million Americans suffer from IBD with 70,000 new cases of the diseases diagnosed each year.
- On the basis of region, North America is estimated to account for the largest market share in the global crohn’s disease treatment market over the forecast period, owing to increasing research and development activities by key players in the region. For instance, in May 2021, in a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company's mirikizumab improved fatigue in patients with moderately to severely active Crohn's disease (CD) at 12 weeks, as measured by the mean change in FACIT-Fatigue scores compared to placebo, with improvements that were sustained up to one year. These results were presented virtually at the Digestive Disease Week (DDW) held between May 21 to 23, 2021. Eli Lilly and Company is a U.S.-based pharmaceutical company.
- Major players operating in the global crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan N.V., Amgen Inc., and AstraZeneca
